ClinicalTrials.gg
CompletedNCT02175355ARAMISUpdated Jul 8, 2014

Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)

A Phase 3 interventional study of Low dose of Micardis® and Medium dose of Micardis® in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 35 Years to 84 Years. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,039
Allocation
Randomized
Ages
35 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.

Enrollment
9th of 74
1,039 · median 381
Started
1999
with 8 others
Phase 3
43 of 122
1 open now
Registered
71st of 122
by date

Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 9th largest by enrollment of the 74 interventional ones that give a count, is one of 9 that started in 1999, is one of 43 in phase 3, and was the 71st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 35 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Hypertension by Boehringer Ingelheim, or all of them as a file.
02

Study summary

Primary: To identify doses of Micardis®(telmisartan) which, administered once daily, are more effective than placebo and not inferior to HCTZ in lowering systolic blood pressure (SBP) in patients with isolated systolic hypertension (ISH), and to assess the dose response relationship of the antihypertensive effect of telmisartan over the dose range of 20 to 80 mg.

Secondary: Target fall in SBP, change from baseline in seated DBP. Safety and tolerability of Micardis® and HCTZ in patients with ISH as measured by changes in physical examinations, heart rate, laboratory parameters and/or 12-lead ECG, as well as the incidence and severity of adverse events.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
35 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 35 years, but less than 85 years of age
  • Mean SBP ≥ 150 mm Hg and mean DBP \< 90 mm Hg at the randomisation visit (visit 2), according to WHO definitions of ISH (excluding the subgroup of borderline ISH)
  • Hypertensive patients not on current antihypertensive therapy or able to stop current treatment for a period of up to 8 - 10 weeks without endangering the health of the patient (investigator's discretion)
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who:

    1. are not surgically sterile; and/or
    2. are nursing
    3. are of and are not practicing acceptable means of or do NOT plan to continue using this method throughout the study. Acceptable methods of birth control include oral, implantable or injectable contraceptives
  • Mean systolic blood pressure ≥ 180 mmHg at the randomization Visit 2
  • Known or suspected secondary hypertension
  • Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    1. Serum glutamic pyruvate transaminase () or serum glutamic oxaloacetic transaminase (AST) > than 2 times the
    2. Serum creatinine > or 1.8 mg/dl (or 159 µmol/l)
  • Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney
  • hypokalemia or hyperkalemia
  • Uncorrected volume or sodium depletion
  • Primary aldosteronism
  • Hereditary fructose intolerance
  • Biliary obstructive disorders
  • Symptomatic congestive heart failure
  • Angina pectoris or previous myocardial infarction
  • Previous percutaneous transluminal coronary angioplasty or coronary artery bypass craft
  • Previous cerebrovascular accident or hypertensive encephalopathy or (s)
  • Current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped (investigators decision) by the start of the run-in period. Any pre-treatment with diuretics, ACE inhibitors or angiotensin II receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate
  • Atrial fibrillation (controlled or otherwise) or any other clinically relevant cardiac arrhythmias as determined by the clinical investigator
  • Hemodynamically relevant aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy or other outflow obstruction of the left ventricle
  • Patients with non-insulin-dependent diabetes mellitus requiring treatment with oral hypoglycemics who fail to meet the following criteria by history:

    1. Fasting blood glucose less than 200 mg/dl (11.1 mmol/l)
    2. Therapy stabilized for at least one month prior to start of placebo run-period
  • Patients with diabetes mellitus requiring treatment with insulin
  • Patients who have previously experienced symptoms characteristics of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
  • Known drug or alcohol dependency
  • Any therapy within one month of signing the form and during the trial
  • Known to any component of the formulation of telmisartan or hydrochlorothiazide including allergy to sulfonamides
  • Concomitant use of lithium or cholestyramine or colestipol resins (potential drug interactions with HCTZ)
  • Gout ( for treatment with HCTZ)
  • Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of telmisartan or hydrochlorothiazide
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,039 participants (actual)

Study arms

  • Experimental
    Low dose of Micardis®

    Drug: Low dose of Micardis®

  • Experimental
    Medium dose of Micardis®

    Drug: Medium dose of Micardis®

  • Experimental
    High dose of Micardis®

    Drug: High dose of Micardis®

  • Active comparator
    Hydrochlorothiazide

    Drug: Hydrochlorothiazide

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugLow dose of Micardis®
  • DrugMedium dose of Micardis®
  • DrugHigh dose of Micardis®
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Change from baseline in seated systolic blood pressure at trough (24 hours post-dose)

    Time frame: after 6 weeks of treatment

  2. Change from baseline in urine albumine excretion rate

    Time frame: after 6 weeks of treatment

  3. Change from baseline in pulse wave velocity

    Time frame: after 6 weeks of treatment

Secondary outcomes

  1. Percentage of patients achieving a target fall in SBP

    Time frame: after 6 weeks of treatment

  2. Changes in seated diastolic blood pressure (DBP)

    Time frame: up to 6 weeks

  3. Change from baseline in augmentation index

    Time frame: after 6 weeks of treatment

  4. Incidence and intensity of adverse events

    Time frame: up to 6 weeks

  5. Number of patients with relevant changes from baseline in physical examination

    Time frame: baseline, week 6

  6. Number of patients with relevant changes in Heart Rate (HR)

    Time frame: up to 6 weeks

  7. Number of patients with relevant changes in laboratory parameters

    Time frame: up to 6 weeks

  8. Number of patients with relevant changes in 12-lead electrocardiogram (ECG)

    Time frame: up to 6 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 1999 and a primary completion of Aug 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2014
First posted
Jun 26, 2014
Start
Oct 1999
Primary completionActual
Aug 2000
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02175355
Responsible party
Sponsor
First posted
Jun 26, 2014
Start date
Oct 1999
Primary completion
Aug 2000
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion